HNF1A and MODY: Previous studies that have determined the levels of N-glycan fucosylation in blood plasma using liquid chromatography (LC) methods showed the excellent performance of the glycan biomarker in differentiating HNF1A-MODY patients in large patient cohorts [17, 18].